Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation

NCT03070119 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03070119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03070119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
March 8, 2017
Completion date
August 12, 2024
Enrollment
139 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

als caused by superoxide dismutase 1 (sod1) mutation